A multivariate analysis certified that EGFR mutation, by contrast, is a more crucial factor for beneficial clinical outcomes in gefitinib-treated NSCLC patients than ErbB2 and EGFR copy numbers [44]. Here, EGFR is linked to non-small cell lung carcinoma.